Sourcing Exosomes in South Dakota
Licensed South Dakota practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. South Dakota buyers need their own professional license and NPI; the wholesale drug distributor license is the supplier’s obligation, not the purchaser’s.
South Dakota pairs a light statutory footprint on regenerative medicine with one of the stronger nurse practice acts in the region: a certified nurse practitioner practices and prescribes independently once 1,040 transition hours are complete, and the collaborator for those hours can be an experienced nurse practitioner rather than a physician. What the state does regulate firmly is upstream of the clinic, in wholesale distribution and embryo research.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to South Dakota? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from South Dakota
ExaVeyra ships to licensed practices in all 50 states, South Dakota included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active South Dakota professional license in good standing, verifiable through the South Dakota Board of Medical and Osteopathic Examiners or the South Dakota Board of Nursing.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A South Dakota exemption certificate through the Department of Revenue if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
South Dakota licenses wholesale distributors of prescription drugs through the Board of Pharmacy under SDCL chapter 36-11A. Section 36-11A-11 requires every out-of-state wholesale drug distributor to obtain a license from the Board before conducting business in the state, with each shipping location licensed separately, and it puts an unusually hard edge on the requirement: acting without the license is a Class 6 felony. The chapter also allows licensure by reciprocity where the distributor holds a comparable license in a state that extends the same treatment to South Dakota distributors. The license sits with the distributor, not with the purchasing practice.
SDCL ch. 36-11A, §§ 36-11A-8, 36-11A-11; ARSD ch. 20:67 · South Dakota Board of Pharmacy
South Dakota regenerative-medicine law
South Dakota has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
South Dakota has enacted no statute addressing unapproved regenerative therapy: no authorization law of the Florida, Texas, or Georgia kind, no disclosure law of the California or Vermont kind, and no documentation statute of the Tennessee kind. What South Dakota does have is a firm research restriction that is regularly mistaken for a practice law: SDCL 34-14-16, enacted in 2000, provides that no person may knowingly conduct nontherapeutic research that destroys a human embryo, a Class 1 misdemeanor. That section restricts embryo research; it neither authorizes nor conditions any clinical service. Practice in this area is governed by the medical practice act in SDCL chapter 36-4, the nurse practice act in SDCL chapter 36-9A, and the boards that administer them, alongside federal law, which is the only layer that addresses the products themselves.
How this applies to exosomes
South Dakota has no stem cell practice statute, so there is no state definition to ask whether exosomes fall inside. The statute most often cited in this area, SDCL 34-14-16, is an embryo research prohibition from 2000 and says nothing about clinical use of any cell or vesicle product. Exosomes are acellular extracellular vesicles, and a perinatal MSC-derived exosome preparation involves no embryo and no embryo research, so the prohibition does not touch it either. In South Dakota exosome products are governed by federal law alone, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a South Dakota practice
South Dakota runs on two models. An experienced CNP-led practice operates on the nurse practitioner’s own authority under SDCL 36-9A, with the statute’s standing expectation in 36-9A-13.1 that the CNP collaborate with other providers and refer or transfer patients as appropriate. A physician-led practice delegates conventionally under the medical practice act. The 1,040-hour transition is the detail to plan around when staffing a new practice with a recently licensed CNP.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the South Dakota Board of Medical and Osteopathic Examiners under SDCL chapter 36-4 perform medical acts within their scope and are the source of delegation in a physician-led practice. Where a corporation employs a physician, SDCL 36-4-8.1 bars the employer from directing the physician’s clinical judgment. |
| NP / APRN | South Dakota certified nurse practitioners practice under SDCL chapter 36-9A with authority to conduct advanced assessments, establish diagnoses, and prescribe, including controlled substances. A CNP with fewer than 1,040 practice hours works under a written collaborative agreement; the collaborator may be a physician, a certified nurse practitioner, or a certified nurse midwife. Once the hours are complete, the CNP practices independently. |
| PA | Physician assistants practice under agreements with supervising physicians within the Board of Medical and Osteopathic Examiners’ framework, in the scope the supervising physician establishes. |
| RN | Registered nurses practice under SDCL chapter 36-9 and carry out treatments on the order of a provider with authority to issue one. An RN does not evaluate the patient independently or set the treatment plan. |
Good faith examination
South Dakota expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Because certified nurse practitioners hold independent authority after the transition period, that provider can be the CNP. The expectations sit in board standards and the practice acts rather than a named good faith examination statute, so confirm current requirements with the Board of Medical and Osteopathic Examiners and the Board of Nursing.
Ownership and clinic licensing
South Dakota codifies its corporate practice doctrine with a built-in safe harbor. SDCL 36-4-8.1 declares the public policy that a corporation may not practice medicine or osteopathy, except as provided in the medical corporation chapter, and then permits a corporation to employ a licensed physician if the agreement does not supplant, diminish, or regulate the physician’s independent judgment, does not produce profit to the corporation from the practice of medicine itself beyond reasonable facility and administrative charges, and does not run longer than three years before annual renewal. Entities practicing medicine directly are organized under the professional corporation framework with licensed ownership. Structure any management arrangement against the statute’s three conditions with South Dakota counsel.
Cold chain into South Dakota
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in South Dakota order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Sioux Falls | Minnehaha | Largest South Dakota market, with the state’s deepest clinical and aesthetic coverage. |
| Rapid City | Pennington | Black Hills hub serving western South Dakota and the Wyoming border. |
| Aberdeen | Brown | Northeastern regional center with a growing clinic base. |
| Brookings | Brookings | University market on the I-29 corridor north of Sioux Falls. |
| Watertown | Codington | Glacial Lakes regional market on the same I-29 lane. |
- South Dakota orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Practice types we supply in South Dakota
South Dakota licensing and verification
South Dakota Board of Medical and Osteopathic Examiners
Licenses physicians and physician assistants.
South Dakota Board of Nursing
Licenses CNPs, who practice independently after 1,040 transition hours.
South Dakota Board of Pharmacy
Licenses the in-state and out-of-state wholesale drug distributors.
South Dakota Department of Revenue
Sales tax licensing and exemption certificates.
South Dakota sourcing questions
- Does South Dakota have a stem cell law?
- No practice law. South Dakota has enacted no stem cell authorization, disclosure, or documentation statute. The section often cited in this area, SDCL 34-14-16, is an embryo research prohibition from 2000: it makes nontherapeutic research that destroys a human embryo a misdemeanor, and it neither authorizes nor restricts any clinical service. Exosome products in South Dakota are governed by federal law, under which no exosome product is FDA approved for administration to humans.
- Can a nurse practitioner run a practice in South Dakota without a physician?
- Yes, within CNP scope, once the transition period is complete. Under SDCL chapter 36-9A a certified nurse practitioner with fewer than 1,040 practice hours works under a written collaborative agreement, and the collaborator can be a physician, an experienced certified nurse practitioner, or a certified nurse midwife. After the hours are complete the CNP evaluates, diagnoses, and prescribes independently, including controlled substances.
- Does South Dakota enforce the corporate practice of medicine?
- In a codified, conditional form. SDCL 36-4-8.1 declares that a corporation may not practice medicine, then permits corporate employment of a physician if the arrangement leaves the physician’s clinical judgment untouched, produces no profit from the medicine itself beyond reasonable facility and administrative charges, and runs no longer than three years before annual renewal. Ownership of an entity that practices medicine directly runs through the professional corporation framework, so structure with South Dakota counsel.
- Does my South Dakota clinic need a wholesale distributor license to buy exosomes?
- No. The out-of-state wholesale drug distributor license under SDCL 36-11A-11 is held by the distributor shipping into South Dakota, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification about exosome products marketed outside that framework. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to South Dakota?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- SDCL 36-11A-11, out-of-state wholesale drug distributor licensing (accessed 16 October 2026)
- SDCL 34-14-16, embryo research prohibition (accessed 16 October 2026)
- SDCL 36-9A-1, APRN definitions and the collaborative agreement (accessed 16 October 2026)
- SDCL 36-4-8.1, corporate practice of medicine (accessed 16 October 2026)
- South Dakota Board of Pharmacy (accessed 16 October 2026)
- South Dakota Board of Nursing (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark characterization standard for extracellular vesicles, the baseline this page assumes when it describes what a defensible exosome Certificate of Analysis reports.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that EV characterization expectations come from the field’s consensus guidelines rather than from any South Dakota statute.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.